Literature DB >> 4010323

Anti-acetylcholine receptor antibody titer with extended thymectomy in myasthenia gravis.

K Kagotani, Y Monden, K Nakahara, Y Fujii, Y Seike, S Kitamura, A Masaoka, Y Kawashima.   

Abstract

Twenty-four patients with myasthenia gravis of Osserman's generalized type underwent extended thymectomy through a sternal-splitting approach. Their clinical responses to thymectomy and postoperative changes in anti-acetylcholine receptor antibody titers were evaluated. The follow-up time ranged from 1 month to 7 years and 7 months (average, 36 months). Six patients (25%) had remissions and 17 patients (71%) were improved after operation. The preoperative anti-acetylcholine receptor antibody titers dropped significantly after operation (p less than 0.001). The postoperative reduction in these titers correlated with the time course after operation (p less than 0.05). Their postoperative reduction was significantly greater in the six patients having remissions than in the 15 having marked (p less than 0.02) and the six having moderate improvement (p less than 0.005). This study has revealed that anti-acetylcholine receptor antibody titer in plasma declines progressively after thymectomy, and the postoperative reduction of this titer correlates with the clinical effect of thymectomy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4010323

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Thymus cells in myasthenia gravis: a two-colour flow cytometric analysis of lymphocytes in the thymus and thymoma.

Authors:  Y Fujii; M Hayakawa; K Nakahara
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

Review 2.  Unraveling the role of ectopic thymic tissue in patients undergoing thymectomy for myasthenia gravis.

Authors:  Feng Li; Ya Tao; Gero Bauer; Aron Elsner; Zhongmin Li; Marc Swierzy; Julianna Englisch; Andreas Meisel; Mahmoud Ismail; Jens-C Rückert
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.